Precious metals are not merely ornaments; they are also important components of pharmaceuticals, like the antitumor drug ...

2025年3月26日，上海市肺科医院陈昶教授与北京大学生物医学前沿创新中心张泽民院士等合作团队，在国际期刊Cell上以Resource形式在线发表了题为“A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer” 的研究论文。陈昶教授及胸外科佘云浪副研究为该论文的 ...

为探究肿瘤免疫微环境（TIME）在非小细胞肺癌（NSCLC）抗 PD-1 治疗中影响疗效的机制，研究人员对 234 例患者术后肿瘤样本进行单细胞 RNA 和 T 细胞受体测序（scRNA/TCR-seq）。发现 5 种 TIME 亚型，明确 T 细胞亚群与疗效及复发的关系，研究成果发表在顶尖学术期刊《Cell》上，为 NSCLC 的治疗开辟了新方向。

Back in 2014, a woman with advanced cancer pushed Adrienne Boire’s scientific life in a whole new direction. The cancer, ...

Mar. 13, 2025 — A discovery about how severe COVID-19 damages lung cells suggests that an existing drug could treat lingering respiratory problems not just from COVID but influenza and other ...

Jan. 6, 2025 — Researchers have developed a way of detecting circulating tumor cells in the bloodstream of pancreatic cancer and lung cancer ... Scientists Develop Scans That Light-Up Aggressive ...

Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients ...

A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for ...

Several pharma CEOs met with Chinese President Xi Jinping in Beijing. President Donald Trump's reciprocal tariffs have mostly ...

Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival ...

An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any metastases with durvalumab vs placebo.